Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) has declared a quarterly dividend of $0.49 per share, an 8.9% increase from last year's $0.45. This dividend will be payable on February 1, 2021 to stockholders of record by January 4, 2021, marking the twelfth consecutive year of increased dividend payouts. Additionally, a quarterly dividend of $0.50 on the company’s convertible preferred stock will be paid on March 1, 2021.
Bristol Myers Squibb (NYSE: BMY) has endowed a $3 million chair in chemistry at Scripps Research to boost drug discovery research. Professor Jin-Quan Yu, a prominent chemist, will be the inaugural holder. This partnership aims to facilitate the translation of academic research into biopharma, enhancing the development of new medicines. The collaboration highlights ongoing efforts to tackle global health challenges through innovative chemistry, with Yu's previous work paving the way for significant advancements in pharmaceutical chemistry.
Bristol Myers Squibb (NYSE: BMY) announced new findings from the QUAZAR® AML-001 study at the 62nd ASH Annual Meeting, highlighting the efficacy of Onureg (azacitidine tablets) for adult patients with acute myeloid leukemia (AML) in first remission. The study demonstrated that Onureg significantly improved overall survival (OS) compared to placebo, with median OS of 14.6 months for MRD+ patients vs. 10.4 months for placebo. Additionally, Onureg showed extended median relapse-free survival (RFS) and reduced hospitalization risks related to AML treatment.
Bristol Myers Squibb (NYSE: BMY) presented data on lisocabtagene maraleucel (liso-cel) at the 62nd ASH Annual Meeting, highlighting its potential in treating relapsed or refractory hematologic malignancies. In the TRANSCEND CLL 004 study, 95% of patients with CLL/SLL responded positively to liso-cel combined with ibrutinib, with high rates of complete responses. The TRANSCEND NHL 001 study indicated an 84% response rate in MCL patients. Additionally, the OUTREACH study showed promising results for liso-cel in LBCL, with 79% of outpatients achieving overall responses.
Bristol Myers Squibb (NYSE: BMY) and bluebird bio presented updated data for investigational CAR T cell therapy idecabtagene vicleucel (ide-cel) at the 62nd ASH Annual Meeting. Key findings from the Phase 1 CRB-401 study indicated an overall response rate (ORR) of 76% among 62 patients with relapsed and refractory multiple myeloma. The median progression-free survival (PFS) was 8.8 months, and median overall survival (OS) reached 34.2 months. Additionally, subgroup analyses revealed consistency in outcomes across high-risk and elderly patient populations.
Bristol Myers Squibb (NYSE: BMY) presented research from nearly 100 studies at the 62nd American Society of Hematology Annual Meeting held from December 5 to 8, 2020. The studies focus on advancements in treating blood cancers and hematologic diseases. Highlights include the latest analyses of CAR T cell therapies like liso-cel and findings on BCMA-targeted therapies for multiple myeloma. The company aims to improve patient outcomes through innovative treatments and ongoing commitment to research, emphasizing the importance of quality of life in treatment.
Bristol Myers Squibb (NYSE: BMY) announced that the European Commission has approved Opdivo (nivolumab) for adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy. The decision, based on the Phase 3 ATTRACTION-3 trial, highlights a 23% reduction in the risk of death with Opdivo compared to chemotherapy, improving median overall survival to 10.9 months. Opdivo's favorable safety profile showed significantly fewer treatment-related adverse events than chemotherapy. This approval allows for expanded treatment options across Europe.
Bristol Myers Squibb (NYSE:BMY) has completed its acquisition of MyoKardia, Inc. for approximately $13.1 billion in cash, enhancing its cardiovascular portfolio. MyoKardia will now operate as a wholly-owned subsidiary. The acquisition brings mavacamten, a potential first-in-class treatment for obstructive hypertrophic cardiomyopathy (HCM), with plans for a New Drug Application to the FDA in Q1 2021. The merger was executed without a vote from MyoKardia’s stockholders, following a successful tender offer for $225 per share, with about 78.9% of shares validly tendered.
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will not complete its review of the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) by the scheduled November 16, 2020 date due to an inability to inspect a third-party manufacturing facility amid COVID-19 restrictions. The BLA remains under review, but no new action date has been provided. This review is critical as FDA approval by December 31, 2020 is a milestone for holders of Contingent Value Rights (CVR) linked to the Celgene acquisition.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Wolfe Research’s 2nd Annual Virtual Healthcare Conference on November 18, 2020. The session, featuring CEO Giovanni Caforio, begins at 9:15 a.m. EST. Investors and the public can access the live webcast at investor.bms.com, with an archived version available later that day. Bristol Myers Squibb is dedicated to developing innovative medicines for serious diseases. For more information, visit BMS.com.